復星醫藥(600196.SH):漢霖製藥注射用曲妥珠單抗藥品註冊補充申請獲受理
格隆匯10月19日丨復星醫藥(600196.SH)公佈,近日,公司控股子公司上海復宏漢霖生物製藥有限公司(以下簡稱“漢霖製藥”)的注射用曲妥珠單抗(即注射用重組抗HER2人源化單克隆抗體,商品名:漢曲優®;以下簡稱“該新藥”)新增“60mg/瓶”規格獲國家藥監局藥品註冊補充申請審評受理。截至2020年9月,集團現階段針對該新藥累計研發投入約為人民幣8.53億元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.